Division of Gastroenterology and Digestive Endoscopy, Humanitas Research Hospital - IRCCS, Milan, Italy.
Division of Gastroenterology and Digestive Endoscopy, Humanitas Research Hospital - IRCCS, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Hepatobiliary Pancreat Dis Int. 2022 Jun;21(3):234-240. doi: 10.1016/j.hbpd.2022.03.003. Epub 2022 Mar 6.
Since it was first described in 2001, endoscopic ultrasonography-guided biliary drainage (EUS-BD) has emerged as an alternative procedure for achieving an endoscopic internal drainage in case of endoscopic retrograde cholangiopancreatography (ERCP) failure. Biliary drainage can be achieved by either a transduodenal extrahepatic approach through EUS-guided choledochoduodenostomy (EUS-CDS), or a transgastric intrahepatic approach, namely EUS-guided hepaticogastrostomy (EUS-HGS) which already holds a remarkable place in the treatment of patients with malignant biliary obstruction.
For this review we did a comprehensive search of PubMed/MEDLINE from inception to May 31, 2021 for papers with a significant sample size (at least 20 patients enrolled) dealing with EUS-HGS. Data on technical success, clinical success and rate of adverse events were collected.
A total of 22 studies with different design, comprising 874 patients, were included. Technical success was achieved in about 96% of cases (ranging from 65% to 100%). Clinical success was obtained in almost 91% of cases (ranging from 76% to 100%). Overall rate of adverse events was 19% (ranging from 0% to 35%). Abdominal pain, self-limiting pneumoperitoneum, bile leak, cholangitis, bleeding, perforation and intraperitoneal migration of the stent were the most common.
Despite both safety and efficacy profile, at the moment HGS still remains a challenging procedure at every single step and must therefore be conducted by a very experienced endoscopist in interventional EUS and ERCP procedures, who is able to deal with the possible severe adverse events of this procedure. A rapid introduction in clinical practice of dedicated devices is desiderable.
自 2001 年首次描述以来,内镜超声引导下胆道引流术(EUS-BD)已成为内镜逆行胰胆管造影术(ERCP)失败时实现内镜内引流的替代方法。胆道引流可通过 EUS 引导的经十二指肠肝外途径(EUS-CDS)或经胃内途径(EUS-HGS)实现,EUS-HGS 已在治疗恶性胆道梗阻患者中占据重要地位。
为了进行本次综述,我们从 2021 年 5 月 31 日开始对 PubMed/MEDLINE 进行了全面搜索,以查找涉及 EUS-HGS 的具有显著样本量(至少纳入 20 例患者)的论文。收集了技术成功率、临床成功率和不良事件发生率的数据。
共纳入 22 项不同设计的研究,包括 874 例患者。技术成功率约为 96%(范围为 65%至 100%)。临床成功率接近 91%(范围为 76%至 100%)。总的不良事件发生率为 19%(范围为 0%至 35%)。腹痛、自限性气腹、胆漏、胆管炎、出血、穿孔和支架腹腔内迁移是最常见的。
尽管具有安全性和疗效,但目前 HGS 仍然是一项具有挑战性的操作,因此必须由在介入性 EUS 和 ERCP 操作方面经验丰富的内镜医生进行,他能够应对该操作可能出现的严重不良事件。迫切需要快速将专用设备引入临床实践。